Viridian Therapeutics, Inc./DE Selling, General and Administrative Expense
Viridian Therapeutics, Inc./DE (VRDN) reported Selling, General and Administrative Expense of $54.98 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE selling, general and administrative expense for the quarter ending 2026-06-30 was $54.98M, a 171.94% increase year-over-year.
- Viridian Therapeutics, Inc./DE selling, general and administrative expense for the quarter ending 2026-03-31 was $38.68M, a 126.15% increase year-over-year.
- Viridian Therapeutics, Inc./DE selling, general and administrative expense for the quarter ending 2025-06-30 was $20.22M.
- Viridian Therapeutics, Inc./DE selling, general and administrative expense for the quarter ending 2025-03-31 was $17.10M.
- Viridian Therapeutics, Inc./DE selling, general and administrative expense for fiscal 2025 was $95.31M, a 56.04% increase from fiscal 2024.
- Viridian Therapeutics, Inc./DE selling, general and administrative expense for fiscal 2024 was $61.08M, a 35.70% decline from fiscal 2023.
- Viridian Therapeutics, Inc./DE selling, general and administrative expense for fiscal 2023 was $95.00M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|
| 2026-06-30 | $54.98M 10-Q · filed 2026-08-06 | $93.65M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $38.68M 10-Q · filed 2026-05-05 | ||
| 2025-12-31 | $95.31M 10-K · filed 2026-02-26 | ||
| 2025-06-30 | $20.22M 10-Q · filed 2026-08-06 | $37.32M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $17.10M 10-Q · filed 2026-05-05 | ||
| 2024-12-31 | $61.08M 10-K · filed 2026-02-26 | ||
| 2023-12-31 | $95.00M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |